Table 1.
Infection fatality risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in community dwelling population by sex and age during the first wave of the covid-19 pandemic in Spain 2020
| Sex, age (years) | No in population (000s) | SARS-CoV-2 seroprevalence (%; 95% CI)* | Individuals with SARS-CoV-2 antibodies (000s; 95% CI) | No of confirmed covid-19 deaths | No of excess all cause deaths | Infection fatality risk (%; 95% CI) | |
|---|---|---|---|---|---|---|---|
| Based on confirmed covid-19 deaths | Based on excess all cause deaths | ||||||
| Overall | 46 887.1 | 4.9 (4.6 to 5.3) | 2305.8 (2152.8 to 2469.1) | 19 228 | 24 778 | 0.83 (0.78 to 0.89) | 1.07 (1.00 to 1.15) |
| Male: | 23 006.9 | 4.8 (4.4 to 5.2) | 1105.1 (1016.9 to 1200.6) | 12 317 | 15 480 | 1.11 (1.02 to 1.21) | 1.40 (1.29 to 1.52) |
| 0-9 | 2205.5 | 3.2 (1.9 to 5.4) | 71.7 (42.5 to 119.7) | 3 | 32 | 0.00 (0.00 to 0.01) | 0.04 (0.02 to 0.08) |
| 10-19 | 2557.9 | 3.6 (2.8 to 4.8) | 93.3 (71.0 to 122.2) | 3 | 0 | 0.00 (0.00 to 0.01) | 0.00 (0.00 to 0.01) |
| 20-29 | 2479.1 | 5.8 (4.7 to 7.1) | 142.7 (116.1 to 174.9) | 18 | 0 | 0.01 (0.01 to 0.02) | 0.00 (0.00 to 0.01) |
| 30-39 | 2978.7 | 4.7 (3.8 to 5.7) | 139.7 (114.0 to 170.9) | 48 | 3 | 0.03 (0.02 to 0.05) | 0.00 (0.00 to 0.01) |
| 40-49 | 3916.7 | 5.3 (4.6 to 6.2) | 209.0 (180.0 to 242.4) | 192 | 168 | 0.09 (0.07 to 0.11) | 0.08 (0.07 to 0.10) |
| 50-59 | 3493.8 | 5.3 (4.5 to 6.1) | 184.0 (157.8 to 214.3) | 705 | 601 | 0.38 (0.32 to 0.45) | 0.33 (0.27 to 0.39) |
| 60-69 | 2598.2 | 4.9 (4.1 to 5.9) | 127.1 (105.3 to 153.2) | 1904 | 2065 | 1.50 (1.24 to 1.82) | 1.62 (1.34 to 1.97) |
| 70-79 | 1783.7 | 4.7 (3.7 to 6.0) | 83.6 (65.4 to 106.5) | 4145 | 5114 | 4.96 (3.87 to 6.33) | 6.12 (4.78 to 7.80) |
| ≥80 | 993.3 | 4.6 (3.2 to 6.5) | 45.6 (31.8 to 64.9) | 5299 | 7497 | 11.6 (8.06 to 16.5) | 16.4 (11.4 to 23.2) |
| Female: | 23 880.1 | 5.0 (4.7 to 5.4) | 1200.5 (1110.5 to 1297.4) | 6911 | 9298 | 0.58 (0.53 to 0.62) | 0.77 (0.71 to 0.84) |
| 0-9 | 2078.3 | 4.2 (2.7 to 6.7) | 88.0 (55.1 to 139.0) | 2 | 11 | 0.00 (0.00 to 0.01) | 0.01 (0.01 to 0.03) |
| 10-19 | 2396.7 | 4.4 (3.4 to 5.6) | 105.1 (81.7 to 134.7) | 3 | 22 | 0.00 (0.00 to 0.01) | 0.02 (0.01 to 0.03) |
| 20-29 | 2404.1 | 5.7 (4.6 to 7.0) | 137.4 (111.2 to 169.3) | 17 | 10 | 0.01 (0.01 to 0.02) | 0.01 (0.00 to 0.01) |
| 30-39 | 3012.4 | 5.2 (4.4 to 6.2) | 156.7 (132.0 to 185.8) | 29 | 71 | 0.02 (0.01 to 0.03) | 0.05 (0.03 to 0.06) |
| 40-49 | 3877.8 | 5.3 (4.6 to 6.2) | 206.8 (177.9 to 240.0) | 103 | 91 | 0.05 (0.04 to 0.06) | 0.04 (0.03 to 0.06) |
| 50-59 | 3563.5 | 5.2 (4.5 to 6.0) | 184.4 (158.8 to 213.8) | 318 | 369 | 0.17 (0.14 to 0.21) | 0.20 (0.17 to 0.24) |
| 60-69 | 2803.4 | 5.0 (4.2 to 6.0) | 140.4 (117.2 to 167.9) | 749 | 875 | 0.53 (0.44 to 0.65) | 0.62 (0.51 to 0.75) |
| 70-79 | 2138.1 | 4.6 (3.7 to 5.8) | 98.9 (79.0 to 123.4) | 1986 | 2646 | 2.01 (1.60 to 2.52) | 2.68 (2.13 to 3.35) |
| ≥80 | 1605.8 | 5.0 (3.7 to 6.8) | 80.2 (58.7 to 108.9) | 3704 | 5203 | 4.62 (3.38 to 6.29) | 6.49 (4.74 to 8.82) |
*
Proportion of participants with detectable IgG antibodies against SARS-CoV-2 in any round of the ENE-COVID nationwide seroepidemiological survey by the chemiluminescent microparticle immunoassay, 27 April-22 June 2020, Spain.